External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology EA4HP SH 2024
Roche and Genentech at

EA4HP SH 2024

September 21 - September 26
Dubrovnik, Croatia
ea4hp.com
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
11:00 AM
Duration 24hrs Dubrovnik, Croatia
An ultrasensitive dual in situ hybridization (ISH) mRNA assay is equivalent in performance to flow cytometry in determination of kappa/lambda (K/L) restriction status in B cell lymphomas and plasma cell malignancies
Bowdoin Su
Oncology | B Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 24hrs Dubrovnik, Croatia
An ultrasensitive dual in situ hybridization (ISH) mRNA in determination of kappa/lambda (K/L) restriction status shows strong concordance with historical light chain restriction in B cell lymphomas and plasma cell malignancies
Bowdoin Su
Oncology | B Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.